Clinical Impact of New Rheumatoid Arthritis Findings From ACR/ARP 2020*

November 5-9, 2020; Virtual Meeting

Review the latest RA management data with Capsule Summaries and expert-authored commentaries covering key studies from ACR/ARP 2020.

Highlights

Slideset

10 Capsule Summary Slidesets

View More

Immunogenicity of Adjuvanted Herpes Zoster Subunit Vaccine in Patients With RA Treated With JAK Inhibitors vs Controls

Lack of Association Between Hydroxychloroquine and Cardiac Events in Patients With RA

Use of a Pharmacogenomics-Driven Machine Learning Approach to Predict Patient Response to Methotrexate

ARCTIC REWIND: Tapering and Withdrawing TNF Inhibitor Associated With Higher Flare Risk in Patients With RA in Stable Remission

SELECT Pooled Analysis: Incidence and Risk Factors for VTE in Patients With RA Treated With Upadacitinib

MONARCH vs MOBILITY: Similar Efficacy With Sarilumab ± MTX in MTX-IR/INT RA

Pooled Analysis of Filgotinib Trials in RA: Incidence and Risk Factors for VTE and MACE

In Multicohort Dutch Study, Most Arthralgia Patients With Subclinical Synovitis Did Not Progress to Inflammatory Arthritis After 3 Yrs

CATCH/CATCH-US Pooled Analysis: Comparison Between Clinician-Assessed vs Patient-Reported CDAI in Patients With Early RA in Telemedicine

SEAM-RA: Maintenance of Remission Better After Withdrawal of Methotrexate Than Withdrawal of Etanercept

Provided by Clinical Care Options, LLC

Contact Info

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from

AbbVie Inc.
Gilead Sciences, Inc.
Sanofi Genzyme Corporation

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.